Anchiano Therapeutics Ltd.
(Note: A public offering: “Our ordinary shares are listed on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol “ANCN.” The last reported sale price of our ordinary shares on the TASE on January 6, 2019 was NIS 9.70, or $2.61, per share (based on the exchange rate reported by the Bank of Israel on that date, which was NIS 3.72 = $1.00).”
We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard of care for early-stage bladder cancer. We have discovered and are developing a biologic agent, inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in effectiveness and problematic in toxicity.
|Address||1/3 High-Tech Village, Givat Ram, P.O. Box 39264 Jerusalem, 9139102 Israel|
|Phone Number||+972 (2) 548-6555|
|View Prospectus:||Anchiano Therapeutics Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-13.4 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$35.0 mil|
|Manager / Joint Managers||Oppenheimer|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|